Gooding Sarah Warren, Felth Lindsey, Foxall Randi, Rosa Zachary, Ireton Kyle, Sall Izabella, Gipoor Joshua, Gaur Anirudh, King Madeline, Dirks Noah, Whistler Cheryl Allyne, Whistler Jennifer Lynne
Center for Neuroscience, University of California-Davis, Davis, CA, United States.
Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, United States.
Front Pharmacol. 2024 Sep 26;15:1438037. doi: 10.3389/fphar.2024.1438037. eCollection 2024.
Opioid drugs are potent analgesics that mimic the endogenous opioid peptides, endorphins and enkephalins, by activating the µ-opioid receptor. Opioid use is limited by side effects, including significant risk of opioid use disorder. Improvement of the effect/side effect profile of opioid medications is a key pursuit of opioid research, yet there is no consensus on how to achieve this goal. One hypothesis is that the degree of arrestin-3 recruitment to the µ-opioid receptor impacts therapeutic utility. However, it is not clear whether increased or decreased interaction of the µ-opioid receptor with arrestin-3 would reduce compulsive drug-seeking.
We utilized three genotypes of mice with varying abilities to recruit arrestin-3 to the µ-opioid receptor in response to morphine in a novel longitudinal operant self-administration model. We also created a quantitative method to define compulsivity in drug-seeking based on a multi-variate analysis of several operant response variables.
We demonstrate that arrestin-3 knockout and wild type mice have highly variable drug-seeking behavior with few genotype differences. In contrast, in mice where the µ-opioid receptor strongly recruits arrestin-3, drug-seeking behavior is much less varied. We found that mice lacking arrestin-3 were more likely to meet the criteria for compulsivity whereas mice with enhanced arrestin-3 recruitment did not develop a compulsive phenotype.
These experiments show that a lack of arrestin-3 is not protective against the abuse liability of morphine in an operant self-administration context. Our data also suggest that opioids that engage both G protein and arrestin-3, recapitulating the endogenous signaling pattern, will reduce abuse liability.
阿片类药物是强效镇痛药,通过激活μ-阿片受体来模拟内源性阿片肽、内啡肽和脑啡肽。阿片类药物的使用受到副作用的限制,包括阿片类药物使用障碍的重大风险。改善阿片类药物的疗效/副作用特征是阿片类药物研究的关键追求,但对于如何实现这一目标尚无共识。一种假设是,β抑制蛋白3募集到μ-阿片受体的程度会影响治疗效用。然而,尚不清楚μ-阿片受体与β抑制蛋白3之间相互作用的增加或减少是否会减少强迫性觅药行为。
在一种新型的纵向操作性自我给药模型中,我们利用了三种基因型的小鼠,它们在对吗啡的反应中募集β抑制蛋白3到μ-阿片受体的能力各不相同。我们还创建了一种定量方法,基于对几个操作性反应变量的多变量分析来定义觅药行为中的强迫性。
我们证明,β抑制蛋白3基因敲除小鼠和野生型小鼠的觅药行为高度可变,基因型差异很小。相比之下,在μ-阿片受体强烈募集β抑制蛋白3的小鼠中,觅药行为的变化要小得多。我们发现,缺乏β抑制蛋白3的小鼠更有可能符合强迫性标准,而β抑制蛋白3募集增强的小鼠没有出现强迫性表型。
这些实验表明,在操作性自我给药的情况下,缺乏β抑制蛋白3并不能预防吗啡的滥用倾向。我们的数据还表明,既能激活G蛋白又能募集β抑制蛋白3、重现内源性信号模式的阿片类药物,将减少滥用倾向。